Nobilis Health is my top pick for Q4, says Mackie’s Stanley

With worldwide markets down substantially heading into the fourth quarter of 2015, Mackie Research Capital analyst Russell Stanley says he has identified a healthcare play that will buck the trend.

In a comprehensive report from Mackie Research Capital dedicated to their analyst’s top picks for Q4, Stanley says Nobilis Health Corp. (Nobilis Health Corp. Stock Quote, Chart, News: NHC-TSX) is his.

Nobilis, which owns and operates ambulatory surgical centers and surgical hospitals in parts of the United States, is a company with a track record of high organic growth, says Stanley. He also notes that Nobilis has a strong track record when it comes to M&A. He points to the company’s September 2014 acquisition of First Nobilis Hospital for $7.5 million in cash, as one example.

On September 23, Nobilis announced it had acquired a 60% stake and management control of the former Freedom Pain Hospital located in Scottsdale, Arizona for approximately $3.2-million.

The analyst says there are macro trends supporting the story as well.

“We view (Nobilis) as an undervalued play on increasing demand for surgical procedures flowing from an aging population and the prevalence of obesity,” says Stanley.

In the research update to clients this morning, Stanley reiterated his “Buy” rating and one year target price of $12.50 on Nobilis Health, implying a return of 72% at the time of publication.

More Cantech Life Sciences

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: nhc
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

View Comments

Recent Posts

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

8 hours ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

18 hours ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

20 hours ago

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

2 days ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

2 days ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

2 days ago